Preparation of medicines for children - A hierarchy of classification

International Journal of Pharmaceutics

Volumn 435, Issue 2, 2012, Pages 124-130

  Ernest, Terry B ^a   Craig, Jo ^a   Nunn, Anthony ^b   Salunke, Smita ^c   Tuleu, Catherine ^c   Breitkreutz, Joerg ^d   Alex, Rainer ^e   Hempenstall, John ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Authorised; Compounding; Extemporaneous; Manipulation; Non authorised; Paediatric

Indexed keywords

CONFERENCE PAPER; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG INFORMATION; DRUG MANUFACTURE; DRUG QUALITY; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; PEDIATRICS; PHARMACEUTICS; PHARMACIST; PRIORITY JOURNAL; SHELF LIFE;

CHILD; DRUG APPROVAL; DRUG COMPOUNDING; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84864709458     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.05.070     Document Type: Conference Paper

References (28)

1. S.M. Abdel-Rahman, F.K. Johnson, G. Gauthier-Dubois, I.E. Weston, and G.L. Kearns The bioequivalence of nizatidine (Axid) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule J. Clin. Pharmacol. 43 2003 148 153
2. Anonymous Electronic Medicines Compendium. COZAAR® 2.5 mg/ml Powder and Solvent for Oral Suspension (Merck, Sharp and Dohme) 2011 http://www.medicines.org.uk/EMC/medicine/21991/SPC/COZAAR+2. 5+mg+ml+powder+and+solvent++for+oral+suspension (accessed 06.07.11)
3. Anonymous Electronic Medicines Compendium. Larium® 250 mg Tablets (Roche) 2011 http://www.medicines.org.uk/EMC/medicine/1701/SPC/Lariam (accessed 06.07.11)
4. Anonymous Siklos SmPC. European Medicines Agency 2011 http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000689/WC500050503.pdf (accessed 06.07.11)
5. Anonymous Electronic Medicines Compendium. Tamiflu® 30 mg and 45 mg Hard Capsules (Roche) 2011 http://www.medicines.org.uk/EMC/medicine/20294/SPC/ Tamiflu+30+mg+and+45+mg+Hard+Capsules (accessed 06.07.11)
6. Anonymous Zestril® (AstraZeneca, USA) Product Information 2011 http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/019777s056lbl.pdf (accessed 06.07.11)
7. F. Brion, A.J. Nunn, and A. Rieutord Extemporaneous (magistral) preparation of oral medicines for children in European hospitals Acta Paediatr. 92 2003 486 490
8. K.J. Christensen, P.O. Gubbins, B.J. Gurley, J.L. Bowman, and R.G. Buice Relative bioavailability of itraconazole from an extemporaneously prepared suspension and from the marketed capsules Am. J. Health Syst. Pharm. 55 1998 261 265
9. European Commission Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use 2001 Available at http://www.ema.europa.eu/docs/en-GB/ document-library/Regulatory-and-procedural-guideline/2009/10/WC500004481.pdf (accessed 06.07.11)
10. EMA Paediatric Regulation 2007 http://ec.europa.eu/health/files/eudralex/ vol-1/reg-2006-1901/reg-2006-1901-en.pdf (accessed 18.03.12)
11. EMA Formulations of Choice for the Paediatric Population 2006 European Medicines Agency London http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003782.pdf (accessed 06.07.11)
12. B.D. Glass, and A. Haywood Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products J. Pharm. Pharm. Sci. 9 2006 398 426
13. Z. Gross Why specials manufacturing units are needed now as much as they ever were Pharm. J. 275 2005 743 746
14. M. Jackson, and A. Lowey Handbook of Extemporaneous Preparation - A Guide to Pharmaceutical Compounding 2010 Pharmaceutical Press London
15. E. Kayitare, C. Vervaet, J.D. Ntawukulilyayo, B. Seminega, V. Bortel, and J.P. Remon Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications Int. J. Pharm. 370 2009 41 46
16. J. Mason, M. Pirmohamed, and T. Nunn Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature Eur. J. Clin. Pharmacol. 68 2011 21 28
17. H. Mulla, N. Hussain, S. Tanna, G. Lawson, B.N. Manktelow, C. Tuleu, N.J. Samani, and H.C. Pandya Assessment of liquid captopril formulations used in children Arch. Dis. Child. 96 2011 293 296
18. M.C. Nahata, and T.F. Hipple Pediatric Drug Formulations 4th edn. 2000 Harvey Whitney Books Co. Cincinnati 0-929375-23-8
19. M.C. Nahata, and L.V. Allen Extemporaneous drug formulation Clin. Ther. 30 2008 2112 2119
20. A.J. Nunn Making medicines that children will take Arch. Dis. Child. 88 2003 369 371
21. J. Raine Off label use of medicine: legal aspects H.S. Thomsen, J.A.W. Webb, Contrast Media: Safety Issues and ESUR Guidelines 2009 Springer London 978-3-540-72783-5
22. H. Shirkey Editorial comment: therapeutic orphans J. Pediatr. 72 1968 119 120
23. J.F. Standing, and C. Tuleu Paediatric formulations - getting to the heart of the problem Int. J. Pharm. 300 2005 56 66
24. The British Pharmacopoeia Commission British Pharmacopoeia 2011 The Stationery Office London 9780113228492
25. C.K. Thompson Extemporaneous formulations: comparison with labelled pediatric formulations Am. Pharm. Rev. March 2010 52 55
26. L.A. Trissel Stability of Compounded Formulations 2000 American Pharmaceutical Association Washington 1-58212-007-2
27. United States Pharmacopeial Convention 2008-9 USP Pharmacists' Pharmacopeia 2nd edn. 2008 United States Pharmacopeial Convention Rockville, MA, USA http://www.usp.org/ (accessed 06.07.11)
28. D.J. Woods Formulation in Pharmacy Practice 2011 http://www. pharminfotech.co.nz/manual/Formulation/oral.htm (accessed 06.07.11)